Literature DB >> 211412

Metabolism of high-density lipoprotein apolipoproteins in Tangier disease.

E J Schaefer, C B Blum, R I Levy, L L Jenkins, P Alaupovic, D M Foster, H B Brewer.   

Abstract

To define the metabolic defect in Tangier disease, we studied the kinetics of [125I]-high-density lipoprotein apolipoproteins (apolipoproteins A-I and A-II) in 11 normal subjects, two obligate heterozygotes, and two homozygotes. Mean synthesis of apolipoproteins A-1 and A-11 was 8.24 mg per kilogram per day in the normal group, 7.94 in heterozygotes and 3.66 in homozygotes. The mean plasma-residence time for both apolipoproteins was 5.21 days in the normal subjects, 3.41 days in heterozygotes, and 0.52 days in homozygotes. In normal subjects and heterozygotes the apolipoproteins were catabolized at similar rates, whereas in homozygotes apolipoprotein A-I was catabolized at a much greater fractional rate than apolipoprotein A-II. These findings indicate that the deficiency of these apolipoproteins in Tangier disease is largely due to rapid and altered catabolism.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 211412     DOI: 10.1056/NEJM197810262991701

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  27 in total

1.  Effluxed lipids: Tangier Island's latest export.

Authors:  M W Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  The composition and metabolism of high density lipoprotein subfractions.

Authors:  E J Schaefer; D M Foster; L L Jenkins; F T Lindgren; M Berman; R I Levy; H B Brewer
Journal:  Lipids       Date:  1979-05       Impact factor: 1.880

Review 3.  Genetic basis of lipoprotein disorders.

Authors:  J L Breslow
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

Review 4.  Molecular regulation of HDL metabolism and function: implications for novel therapies.

Authors:  Daniel J Rader
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

Review 5.  HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease.

Authors:  H Bryan Brewer
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

Review 6.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

7.  Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease.

Authors:  Suzanne E Wahrle; Hong Jiang; Maia Parsadanian; Jungsu Kim; Aimin Li; Amanda Knoten; Sanjay Jain; Veronica Hirsch-Reinshagen; Cheryl L Wellington; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

8.  Comparative in vitro study of the pro-apolipoprotein A-I to apolipoprotein A-I converting activity between normal and Tangier plasma.

Authors:  C Edelstein; J I Gordon; C A Vergani; A L Catapano; V Pietrini; A M Scanu
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

9.  Tangier disease: defective recombination of a specific Tangier apolipoprotein A-I isoform (pro-apo A-i) with high density lipoproteins.

Authors:  G Schmitz; G Assmann; S C Rall; R W Mahley
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

10.  Human apolipoprotein A-IV. Intestinal origin and distribution in plasma.

Authors:  P H Green; R M Glickman; J W Riley; E Quinet
Journal:  J Clin Invest       Date:  1980-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.